Get the Stockscreener App
2.80
3.32%
0.09
After Hours:
2.80
Lite Strategy Inc stock is traded at $2.80, with a volume of 2.24M.
It is up +3.32% in the last 24 hours and up +0.00% over the past month.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor.
See More
Previous Close:
$2.71
Open:
$2.74
24h Volume:
2.24M
Relative Volume:
19.91
Market Cap:
$91.95M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.59
$2.87
1-Week Range:
$2.59
$3.03
52-Week Range:
$2.59
$3.03
Lite Strategy Inc Stock (LITS) Company Profile
Name
Lite Strategy Inc
Sector
Industry
Phone
858-369-7100
Address
11455 EL CAMINO REAL, SAN DIEGO
Compare LITS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LITS
Lite Strategy Inc
|
2.80 | 88.99M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Lite Strategy Inc Stock (LITS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Downgrade | Laidlaw | Buy → Hold |
| Mar-25-22 | Downgrade | Jefferies | Buy → Hold |
| Mar-25-22 | Downgrade | Stifel | Buy → Hold |
| Mar-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-03-22 | Initiated | Jefferies | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-29-20 | Initiated | SunTrust | Buy |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Jul-27-18 | Upgrade | Stifel | Hold → Buy |
| Jul-13-18 | Initiated | SunTrust | Buy |
| Apr-18-16 | Reiterated | Wedbush | Neutral |
| Mar-23-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-18-14 | Reiterated | ROTH Capital | Buy |
| Oct-16-14 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Brean Capital | Buy |
| Oct-22-13 | Reiterated | Stifel | Buy |
| Apr-15-13 | Initiated | Stifel | Buy |
View All
Lite Strategy Inc Stock (LITS) Latest News
MEI PHARMA, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) - MarketScreener
Lite Strategy: From Biotech To Litecoin Treasury (NASDAQ:LITS) - Seeking Alpha
Lite Strategy Investor Exercises Warrants in Cashless Deal - TipRanks
Lite Strategy with New NASDAQ Ticker ‘LITS’ Enters the Public Market - CryptoNinjas
LITS Stock Price and Chart — NASDAQ:LITS - TradingView
MEI Pharma, Inc will Change its Name to Lite Strategy, Inc - MarketScreener
MEI Pharma Rebrands to Lite Strategy, Inc. - TipRanks
MEI Pharma rebrands as Lite Strategy, adopts Litecoin as treasury asset - Investing.com
MEI Pharma rebrands as Lite Strategy, adopts Litecoin as treasury asset By Investing.com - Investing.com Nigeria
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’ - Business Wire
Lite Access Technologies Expands Through Strategic Acquisition of Ironman - MSN
MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising - Business Wire
MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange - Business Wire
Biotech Pioneer Converts $100M Treasury to Litecoin as Charlie Lee Joins Board - Stock Titan
Damon CEO Showcases Asset-Light Strategy, HyperSport Development, and Revolutionary Damon™ I/O Platform in WebBikeWorld Feature Article - Yahoo Finance
NUBURU Stockholders Green-Light Strategy to Finance Transformation in Key Stockholder Vote - Yahoo Finance
Lennar De-Risking Portfolio Through Strategic Shift - Forbes
Clorox's Innovations on Track: Kingsford & Miller Lite Bring Beercoal - Yahoo Finance
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position - Business Wire
Navigating Retail and Specialty Lite Success: How Your Pharmacy Strategy Impacts Brand Performance - Fierce Pharma
Centurion Corp Poised for Continued Growth with Expanding Pipeline and Asset-Light Strategy - Minichart
From ‘Aisle to Algorithm': David's Bridal Unveils Digital-First Transformation to Become Wedding Industry's Leading Retailer and Media & Planning Marketplace - Newswire.com
Focus on an ‘asset-light’ strategy reason why Melco Resorts considers options for City of Dreams Manila: Lawrence Ho - GGRAsia
Sharp advances asset-light strategy with US$159.06 million sale to Sekisui Chemical - digitimes
Is CapitaLand’s Asset-Light Strategy Losing Its Shine? - Minichart
Lite Bite Foods in talks to sell minor stake to strategic investors - The Economic Times
Lennar: A Solid Investment With Its Land-Light Strategy - Seeking Alpha
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position - MarketScreener
How asset-light business models can boost financial performance - EY
Jim Cramer on Starbucks Corporation (SBUX): ‘Will Starbucks Adopt A So-Called China Lite Strategy Under New CEO Brian Niccol?’ - Yahoo Finance
MEI Pharma Reports Fiscal Year End 2024 Cash Position - Business Wire
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives - MarketScreener
An Post: New Green Light 2028 strategy will grow company to a €1bn business - Post & Parcel
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) - MarketScreener
High-end hotels and asset light model suit Hyatt strategy - Hospitality Investor
By Light Announces Strategic Market Expansion into the United Kingdom - Send2Press
Minor uses asset-light strategy - bangkokpost.com
MEI Pharma, Inc. Announces Board Changes - MarketScreener
MEI Pharma Announces Results of Special Meeting of Stockholders - MarketScreener
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals - MarketScreener
Mei Pharma, Inc. Announces Executive Changes - MarketScreener
MEI Pharma, Inc. Announces Executive Changes - MarketScreener
MEI Pharma Announces 1-for-20 Reverse Stock Split - Business Wire
MEI Pharma, Inc. Announces Management Changes - MarketScreener
MEI PHARMA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) - MarketScreener
MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors - MarketScreener
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress - MarketScreener
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022 - MarketScreener
MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments - MarketScreener
CANOmni-Lite Industries Announces Strategic Acquisition of Designed Precision Castings Following the Completion of the Sale and Leaseback of the Company’s California Real Estate Assets - foundry-planet.com
MEI Pharma : January 2022 Corporate Presentation - MarketScreener
Lite Strategy Inc Stock (LITS) Financials Data
There is no financial data for Lite Strategy Inc (LITS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.43%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):